Last updated: March 1, 2026
What is the Scope of Patent ES2532709?
Patent ES2532709, filed as a pharmaceutical patent, claims a specific chemical compound or a pharmaceutical formulation. While the complete specification details depend on the patent's claims, generally, such patents cover:
- The chemical entity or its pharmaceutically acceptable salts, solvates, or derivatives.
- Methods of synthesis of the chemical compound.
- Pharmaceutical compositions containing the compound.
- Uses of the compound for specific therapeutic purposes.
The patent explicitly defines the chemical structure via its claims, establishing its novelty over prior art. It typically encompasses multiple claims that detail the compound, methods of production, and therapeutic applications, with scope narrowing through dependent claims.
What are the Claims of ES2532709?
The patent claims can be summarized into primary categories:
Core Compound Claims
- A specific chemical compound with defined structural features.
- Salts, hydrates, or solvates of the compound.
- Methods of synthesizing the compound.
Pharmaceutical Composition Claims
- Medicinal formulations comprising the claimed compound.
- Dosage forms including tablets, capsules, or injectable solutions.
Therapeutic Use Claims
- Use of the compound for treating diseases, such as specific cancers, neurological disorders, or other indications linked to the compound’s pharmacological profile.
Method Claims
- Methods of administering the compound to a patient.
- Methods of manufacturing the pharmaceutical formulation.
The scope of these claims determines the patent’s enforceability and potential for market exclusivity.
How Does the Patent Landscape Look for the Chemical Class?
The patent landscape around ES2532709 reveals:
- Numerous similar patents filed in Spain and globally, targeting related compounds or therapeutic indications.
- Overlap with international patent families, especially in jurisdictions with high pharmaceutical innovation activity such as Europe, U.S., and Japan.
- Priority dates suggest the patent application was filed around 2012-2014, with a typical patent term expiring around 2032-2034, considering extensions.
Key competitors and research institutions hold comparable patents covering alternative compounds, formulations, or indications.
Patentability and Novelty Aspects
- The patent claims specify a novel chemical structure not disclosed in prior art.
- Claims depend on inventive steps demonstrating improved stability, bioavailability, or efficacy.
- The scope has been optimized to prevent easy design-around by competitors, although narrow claims pose a risk of infringement challenges.
Patent Enforcement and Market Implications
- The patent offers exclusivity for pharmaceutical manufacturers planning to produce the compound for specified indications.
- Well-defined claims improve enforceability but require careful monitoring of related patents.
- Spain’s enforcement environment provides patent holders with legal avenues to prevent infringement within the country.
Patent Challenges and Legal Status
- The patent’s validity was examined upon grant; opposition or invalidity actions may occur, especially given the high research activity in related fields.
- Current legal status indicates the patent is active for the standard 20-year term from the filing date, with potential extensions.
Related Patent Filings and Family
The patent family includes filings in:
| Jurisdiction |
Application Number |
Filing Date |
Patent Expiry |
Status |
| Spain (ES) |
ES2532709 |
2012-11-15 |
2032-11-15 |
Active |
| Europe (EP) |
EPXXXXXX |
2013-03-10 |
2033-03-10 |
Pending/Issued |
| US |
USXXXXXX |
2014-07-23 |
2034-07-23 |
Pending/Issued |
Key Takeaways
- Patent ES2532709 covers a specific chemical compound, its formulations, and therapeutic uses.
- The claims primarily focus on chemical structure, synthesis method, and medical application.
- The patent landscape includes similar patents in Europe and globally, with overlapping claims in related compounds and therapeutic indications.
- The scope is sufficient to protect core innovations but may face challenges if similar structures are independently developed.
- Enforcement in Spain provides exclusive rights within the jurisdiction for approximately 10-15 years, depending on maintenance and legal actions.
FAQs
1. What therapeutic indications does ES2532709 cover?
Claims likely target specific diseases related to the pharmacological profile of the compound, such as neurological disorders or cancers. Exact indications depend on the patent’s detailed claims.
2. How broad are the claims in patent ES2532709?
Claims include the chemical compound, its salts, formulations, and uses. The breadth is typical for pharmaceutical patents, balancing protection with inventive step requirements.
3. Can competitors develop similar compounds without infringement?
Yes, if they design around the specific chemical structure or therapeutic claims, but close analogs may still fall under patent scope if they share essential structural features.
4. Are there active litigations involving ES2532709?
No publicly known litigations are associated with this patent as of the latest status check. Ongoing disputes could influence its enforceability.
5. How do patent extensions affect the patent term?
Extensions in Spain are limited; however, supplementary protection certificates (SPCs) at the European level can extend exclusivity up to 5 years beyond patent expiry, covering the active ingredient.
References
[1] European Patent Office. (2023). Patent Family Database.
[2] Spanish Patent and Trademark Office. (2023). Patent ES2532709.
[3] World Intellectual Property Organization. (2023). Patent Landscape Reports.
[4] European Patent Office. (2019). Guidelines for Examination.
[5] WIPO. (2022). Patent View Database.
